Event JSON
{
"id": "935f415a30cbdd9ce63670ec13538d71ef821dc6cb07754aa445811f8f2ec340",
"pubkey": "61e9f37dc1239bee14634b27a3ea2a5f7d06e254648349b3886c042939936499",
"created_at": 1786899722,
"kind": 1,
"tags": [
[
"proxy",
"https://wandering.shop/@adapalmer/117106260180927505",
"web"
],
[
"t",
"sharegoodnewstoo"
],
[
"proxy",
"https://wandering.shop/users/adapalmer/statuses/117106260180927505",
"activitypub"
],
[
"L",
"pink.momostr"
],
[
"l",
"pink.momostr.activitypub:https://wandering.shop/users/adapalmer/statuses/117106260180927505",
"pink.momostr"
],
[
"-"
]
],
"content": "The first new tuberculosis vaccine in a century is heading for mass production. India’s Serum Institute will manufacture M72/AS01E under an agreement with the Gates Medical Research Institute, investing more than $100 million ahead of approval. TB still kills 1.23 million people a year. WHO estimates a vaccine with this efficacy profile could prevent 76 million cases and save 8.5 million lives over 25 years. Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/indias-serum-institute-partners-with-gates-mri-make-expiremental-tb-vaccine-2026-07-16/\n#ShareGoodNewsToo",
"sig": "9a61818e41a91d0227c4624478c622f486cd060da786fa7d09af963489aaf8d0817cbfb97445569b782524b81da899a6d7fb873e3e3c0adc4e7684bb610dd7b7"
}